Resveratrol ameliorates rheumatoid arthritis via activation of SIRT1-Nrf2 signaling pathway.
Gaoyuan Wang, Xinxin Xie, Lingli Yuan...
https://pubmed.ncbi.nlm.nih.gov/31883358Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID07089381
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis
Led by Ain Shams University · Updated on 2025-07-28
118
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of resveratrol in adults with moderate to high active rheumatoid arthritis (RA). The study aims to understand how resveratrol impacts inflammation, oxidative stress, disease activity, and quality of life in patients already receiving standard RA treatment. The trial is sponsored by Ain Shams University and involves 118 eligible patients randomly assigned to two groups. One group will receive standard RA treatment plus a daily 1 gram dose of resveratrol for three months, while the other group will receive only the standard treatment for the same period. Resveratrol is given as a single 1000 mg tablet once daily. Patients are monitored for 3 months during treatment. Participants will undergo assessments of inflammation and oxidative stress by measuring serum markers such as Sirtuin 1 (SIRT1), Myeloperoxidase (MPO), and C-reactive protein (CRP). Disease activity will be evaluated using the DAS28 score, and quality of life will be measured using the Health Assessment Questionnaire Disability Index (HAQ-DI). Researchers will also monitor for any adverse effects related to resveratrol throughout the study period, which lasts from 3 to 6 months.
CONDITIONS
Brief Title
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adult patients over 18 years old
- Established diagnosis of rheumatoid arthritis according to ACR/EULAR 2010 criteria
- Moderate to high disease activity with DAS28-CRP score greater than 3.2
- Receiving stable regimen of conventional synthetic DMARDs for at least the past 3 months
You will not qualify if you...
- Receiving biologic DMARDs therapy for rheumatoid arthritis
- Taking any other anti-inflammatory drugs
- Taking any other antioxidants
- Pregnant or lactating women
- Other rheumatological, inflammatory diseases or malignancies
- Smokers
- Thyroid illnesses
- Impaired liver function with transaminases three times above normal limits
- Impaired kidney function with eGFR less than 30 ml/min
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 3 months
Participants receive standard treatment for rheumatoid arthritis, with some receiving Resveratrol 1 gm daily in addition to standard treatment, for 3 months.
Regular visits during treatment period as per usual care
Follow-up
Duration - 3 months
Participants are monitored to investigate effects on inflammation, disease activity, and quality of life after treatment ends.
Visits from 3 to 6 months after treatment begins
Trial Site Locations
Total: 1 location
1
Department of Rheumatology at Ain Shams university hospital, Cairo, Egypt
Cairo, Egypt
Actively Recruiting
Loading map...
Research Team
R
Rana El-Dash, MsC
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Therapeutic Potential of Plant-Derived Compounds and Plant Extracts in Rheumatoid Arthritis-Comprehensive Review.
Mateusz Kciuk, Anjali Garg, Manni Rohilla...
https://pubmed.ncbi.nlm.nih.gov/39061843The burden of rheumatoid arthritis in the Middle East and North Africa region, 1990-2019.
Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi, Alireza Khabbazi...
https://pubmed.ncbi.nlm.nih.gov/36369238Role of Sirtuins in the Pathogenesis of Rheumatoid Arthritis.
Agata Poniewierska-Baran, Oliwia Bochniak, Paulina Warias...
https://pubmed.ncbi.nlm.nih.gov/36675041Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes.
Beatriz Isabel García-Martínez, Mirna Ruiz-Ramos, José Pedraza-Chaverri...
https://pubmed.ncbi.nlm.nih.gov/37108584Resveratrol Role in Autoimmune Disease-A Mini-Review.
Ana Lígia de Brito Oliveira, Valter Vinicius Silva Monteiro, Kely Campos Navegantes-Lima...
https://pubmed.ncbi.nlm.nih.gov/29194364Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study.
Hani M Khojah, Sameh Ahmed, Mahran S Abdel-Rahman...
https://pubmed.ncbi.nlm.nih.gov/29611086